Literature DB >> 2960781

Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders.

P J Whitehouse1, K J Kellar.   

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) and to a lesser extent progressive supranuclear palsy are characterized by dysfunction of the cholinergic basal forebrain neurons which send projections to cortex and other areas of the telencephalon. In this paper we demonstrate that this cholinergic dysfunction is associated with consistent reductions in density of cortical nicotinic but not muscarinic cholinergic receptors in these disorders. These cholinergic abnormalities are not found in Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960781

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  8 in total

Review 1.  Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine.

Authors:  E L Ochoa; L Li; M G McNamee
Journal:  Mol Neurobiol       Date:  1990 Fall-Winter       Impact factor: 5.590

Review 2.  Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease.

Authors:  M-Marsel Mesulam
Journal:  J Comp Neurol       Date:  2013-12-15       Impact factor: 3.215

3.  Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs.

Authors:  Joseph A Araujo; Nigel H Greig; Donald K Ingram; Johan Sandin; Christina de Rivera; Norton W Milgram
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.

Authors:  J R Atack; I Litvan; L J Thal; C May; S I Rapoport; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

Review 5.  Nicotine-related brain disorders: the neurobiological basis of nicotine dependence.

Authors:  E L Ochoa
Journal:  Cell Mol Neurobiol       Date:  1994-06       Impact factor: 5.046

6.  Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

Authors:  N Pomara; M Stanley; P A LeWitt; M Galloway; R Singh; D Deptula
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 7.  Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.

Authors:  Gary X D'Souza; Henry J Waldvogel
Journal:  J Huntingtons Dis       Date:  2016-12-15

Review 8.  Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.

Authors:  Enrique L M Ochoa; Jose Lasalde-Dominicci
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.